CA2398775A1 - Nouvel inhibiteur de l'activateur du facteur de croissance des hepatocytes, utile pour moduler l'angiogenese et la cardiovascularisation - Google Patents
Nouvel inhibiteur de l'activateur du facteur de croissance des hepatocytes, utile pour moduler l'angiogenese et la cardiovascularisation Download PDFInfo
- Publication number
- CA2398775A1 CA2398775A1 CA002398775A CA2398775A CA2398775A1 CA 2398775 A1 CA2398775 A1 CA 2398775A1 CA 002398775 A CA002398775 A CA 002398775A CA 2398775 A CA2398775 A CA 2398775A CA 2398775 A1 CA2398775 A1 CA 2398775A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- acid sequence
- nucleic acid
- mammal
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
Abstract
L'invention concerne des compositions et procédés de stimulation ou d'inhibition de l'angiogenèse et/ou de la cardiovascularisation, chez des mammifères, et notamment chez l'homme. Des compositions pharmaceutiques, à base de polypeptides ou d'antagonistes de ces polypeptides, ont été identifiées qui conviennent à l'une, au moins, de ces utilisations. Des troubles diagnostiqués, prévenus ou traités au moyens de ces compositions, comprennent des traumas, tels que des plaies, divers cancers, et des pathologies des vaisseaux, notamment l'athérosclérose et l'hypertrophie cardiaque. En outre, l'invention concerne des nouveaux polypeptides ainsi que des molécules d'acides nucléiques codant pour ces polypeptides, de même que des vecteurs et cellules hôtes comprenant ces séquences d'acides nucléiques, des molécules de polypeptides chimères comprenant les polypeptides de l'invention fusionnés à des séquences de polypeptides hétérologues, des anticorps se liant aux polypeptides de l'invention, ainsi que des procédés de production de ces polypeptides.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/003565 WO2001053486A1 (fr) | 1999-03-08 | 2000-02-11 | Compositions et procedes destines au traitement de tumeur |
USPCT/US00/03565 | 2000-02-11 | ||
PCT/US2000/006884 WO2001005972A1 (fr) | 1999-07-20 | 2000-03-15 | Compositions et methodes pour traiter des maladies d'ordre immunologique |
USPCT/US00/06884 | 2000-03-15 | ||
US25366500P | 2000-11-28 | 2000-11-28 | |
US60/253,665 | 2000-11-28 | ||
PCT/US2000/034756 WO2001059100A2 (fr) | 2000-02-11 | 2000-12-19 | Nouvel inhibiteur de l'activateur du facteur de croissance des hepatocytes, utile pour moduler l'angiogenese et la cardiovascularisation |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2398775A1 true CA2398775A1 (fr) | 2001-08-16 |
Family
ID=39048807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002398775A Abandoned CA2398775A1 (fr) | 2000-02-11 | 2000-12-19 | Nouvel inhibiteur de l'activateur du facteur de croissance des hepatocytes, utile pour moduler l'angiogenese et la cardiovascularisation |
Country Status (13)
Country | Link |
---|---|
US (2) | US6800604B2 (fr) |
EP (1) | EP1255829B1 (fr) |
JP (2) | JP2003527844A (fr) |
AT (1) | ATE440139T1 (fr) |
AU (1) | AU3075701A (fr) |
CA (1) | CA2398775A1 (fr) |
CY (1) | CY1109518T1 (fr) |
DE (1) | DE60042793D1 (fr) |
DK (1) | DK1255829T3 (fr) |
ES (1) | ES2330918T3 (fr) |
IL (2) | IL150987A0 (fr) |
PT (1) | PT1255829E (fr) |
WO (1) | WO2001059100A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030119113A1 (en) * | 1999-07-20 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2003277283A1 (en) * | 2002-10-07 | 2004-05-04 | Genentech, Inc. | Hepatocyte growth factor variants |
WO2004104215A2 (fr) * | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Approches diagnostiques et therapeutiques des maladies associees a la dipeptidylpeptidase 7 (dpp7) |
TWI476206B (zh) * | 2003-07-18 | 2015-03-11 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
BRPI0510206A (pt) * | 2004-05-12 | 2007-10-16 | Genentech Inc | método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação |
EP1815206B1 (fr) | 2004-10-13 | 2016-04-06 | PTC Therapeutics, Inc. | Composes de suppression de non-sens et procedes de leur utilisation |
JP2010540534A (ja) | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
AR078667A1 (es) * | 2009-10-19 | 2011-11-23 | Genentech Inc | Moduladores de activador del factor de crecimiento de hepatocitos (hgfa) |
US20110206704A1 (en) * | 2009-10-19 | 2011-08-25 | Genentech, Inc. | Methods and compositions for modulating hepatocyte growth factor activator |
US20130149788A1 (en) * | 2011-12-09 | 2013-06-13 | Cornell University | Assay for quantifying elemental sulfur levels in a sample |
US10743996B2 (en) * | 2017-03-24 | 2020-08-18 | Robert L. Bundy | Amnion putty for cartilage repair |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US5382569A (en) | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
ATE522621T1 (de) | 1993-04-05 | 2011-09-15 | Univ Utah Res Found | Diagnose und behandlung von williams syndrom |
US5773223A (en) | 1993-09-02 | 1998-06-30 | Chiron Corporation | Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof |
US5610134A (en) | 1994-04-15 | 1997-03-11 | Genentech, Inc. | Treatment of congestive heart failure |
US5661122A (en) | 1994-04-15 | 1997-08-26 | Genentech, Inc. | Treatment of congestive heart failure |
US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
DK0755446T3 (da) | 1994-04-25 | 2007-01-29 | Genentech Inc | Cardiotrophin og anvendelser deraf |
US5573762A (en) | 1995-04-24 | 1996-11-12 | Genentech, Inc. | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy |
EP0759467B1 (fr) | 1995-07-24 | 2004-02-11 | Mitsubishi Chemical Corporation | Inhibiteur d'activateur du facteur de croissance d'hépatocyte |
AU7254896A (en) | 1995-10-05 | 1997-04-28 | Genentech Inc. | Improved angiogenesis using hepatocyte growth factor |
JPH1135480A (ja) * | 1997-07-15 | 1999-02-09 | Mitsubishi Chem Corp | プロテアーゼの活性亢進に起因する疾患の予防及び/または治療剤 |
CA2375458A1 (fr) | 1999-07-20 | 2001-01-25 | Genentech, Inc. | Compositions et methodes pour traiter des maladies d'ordre immunologique |
-
2000
- 2000-12-19 DE DE60042793T patent/DE60042793D1/de not_active Expired - Lifetime
- 2000-12-19 JP JP2001558238A patent/JP2003527844A/ja active Pending
- 2000-12-19 AU AU30757/01A patent/AU3075701A/en not_active Abandoned
- 2000-12-19 ES ES00990950T patent/ES2330918T3/es not_active Expired - Lifetime
- 2000-12-19 CA CA002398775A patent/CA2398775A1/fr not_active Abandoned
- 2000-12-19 EP EP00990950A patent/EP1255829B1/fr not_active Expired - Lifetime
- 2000-12-19 WO PCT/US2000/034756 patent/WO2001059100A2/fr active Application Filing
- 2000-12-19 PT PT00990950T patent/PT1255829E/pt unknown
- 2000-12-19 IL IL15098700A patent/IL150987A0/xx unknown
- 2000-12-19 DK DK00990950T patent/DK1255829T3/da active
- 2000-12-19 US US09/742,201 patent/US6800604B2/en not_active Expired - Lifetime
- 2000-12-19 AT AT00990950T patent/ATE440139T1/de active
-
2002
- 2002-07-30 IL IL150987A patent/IL150987A/en not_active IP Right Cessation
-
2003
- 2003-12-11 US US10/733,890 patent/US20040132660A1/en not_active Abandoned
-
2009
- 2009-10-26 CY CY20091101110T patent/CY1109518T1/el unknown
-
2012
- 2012-07-19 JP JP2012160868A patent/JP2012246296A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20040132660A1 (en) | 2004-07-08 |
WO2001059100A2 (fr) | 2001-08-16 |
IL150987A0 (en) | 2003-02-12 |
JP2012246296A (ja) | 2012-12-13 |
US20020123091A1 (en) | 2002-09-05 |
EP1255829A2 (fr) | 2002-11-13 |
CY1109518T1 (el) | 2014-08-13 |
WO2001059100A3 (fr) | 2001-12-20 |
EP1255829B1 (fr) | 2009-08-19 |
US6800604B2 (en) | 2004-10-05 |
ATE440139T1 (de) | 2009-09-15 |
AU3075701A (en) | 2001-08-20 |
ES2330918T3 (es) | 2009-12-17 |
PT1255829E (pt) | 2009-11-26 |
JP2003527844A (ja) | 2003-09-24 |
DE60042793D1 (de) | 2009-10-01 |
IL150987A (en) | 2009-09-01 |
DK1255829T3 (da) | 2009-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU771751C (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
AU768694B2 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
WO2000053753A2 (fr) | Activation ou inhibition de l'angiogenese et de la cardiovascularisation | |
JP2012246296A (ja) | 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター | |
JP2003531811A5 (fr) | ||
JP2009019032A (ja) | 血管形成及び心臓血管新生の促進又は阻害 | |
WO2000053752A2 (fr) | Activation ou inhibition de l'angiogenese et de la cardiovascularisation | |
WO2001040464A1 (fr) | Kinase 3 associee au recepteur de l'interleukine 1 (irak3) et son utilisation pour stimuler ou inhiber l'angiogenese et la cardiovascularisation | |
AU5920099A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
EP2042597B1 (fr) | Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse | |
AU2003259607B2 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
WO2001019987A1 (fr) | Promotion ou inhibition de l'angiogenese et de la vascularisation cardiaque | |
NZ532803A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
ZA200105990B (en) | Promotion or inhibition of angiogenesis and cardiovascularization. | |
NZ535590A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
NZ540754A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
NZ545534A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
ZA200103707B (en) | Promotion or inhibition of angiogenesis and cardio-vascularization. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |